Telix Pharmaceuticals Ltd Half-Year Financial Report H1 2026
Key points
- Revenue increased by 22% to $477.3 million
- Net profit of $38.3 million compared to a loss of $2.3 million in H1 2025
- Strategic collaboration with Regeneron Pharmaceuticals for radiopharmaceutical therapies
- Expansion of manufacturing and distribution capabilities
Full summary
Telix Pharmaceuticals Ltd reported strong financial results for the half-year ended June 30, 2026, with total revenue increasing by 22% to $477.3 million compared to $390.4 million in the same period last year. The company reported a net profit of $38.3 million, a significant improvement from the loss of $2.3 million in H1 2025. The growth was driven by increased demand for Illuccix and Gozellix in the U.S. and contributions from RLS Radiopharmacies. Telix also announced a strategic collaboration with Regeneron Pharmaceuticals to develop and commercialize next-generation radiopharmaceutical therapies. Additionally, the company expanded its manufacturing and distribution capabilities, including opening a new facility in partnership with the Melbourne Theranostic Innovation Centre.
Guidance
Revenue expected to grow by 20-25% for FY26
Outlook
Telix Pharmaceuticals expects continued revenue growth driven by the success of Illuccix and Gozellix, the launch of new imaging agents, and the advancement of its therapeutic pipeline.
Summary generated by a large language model. Please interpret with care.